OncoMatch

OncoMatch/Clinical Trials/NCT03368651

The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Is NCT03368651 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for hepatocellular carcinoma.

Phase 3RecruitingSun Yat-sen UniversityNCT03368651Data as of Jun 2026Location: China

To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: any prior treatment (including interferon)

not previous treated for tumor; be treated before (interferon included)

Lab requirements

Blood counts

neutrophil count≥2.0×10^9/L; hemoglobin≥100g/L; platelet count≥75×10^9/L; PT≤upper limit of normal plus 4 seconds; INR≤2.2

Kidney function

serum creatine<1.5-times upper limit of normal

Liver function

serum albumin≥35g/L; total bilirubin<2-times upper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit of normal

the lab test could meet: neutrophil count≥2.0×10^9/L; hemoglobin≥100g/L; platelet count≥75×10^9/L; serum albumin≥35g/L; total bilirubin<2-times upper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit of normal; serum creatine<1.5-times upper limit of normal; PT≤upper limit of normal plus 4 seconds; INR≤2.2

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT03368651 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify